The tweet was deleted by the author.
But we saved everything 🙂.
Definium Therapeutics brought together lawmakers, clinical researchers, and advocates in the nation's capital to focus on ongoing research in psychedelic medicines and the future direction of these treatments.
The discussions underscored the growing importance of innovation in the field of psychiatry, as stakeholders explored how emerging therapies could reshape mental health care. The meeting signals continued interest and potential policy momentum around psychedelic-based psychiatric treatments.
View post on X Loading...
Definium recently began patient dosing in Ascend, its second Phase 3 pivotal trial for major depressive disorder. The company also took part in Fierce Biotech Week, where its Chief Corporate Affairs Officer joined an industry panel with other communications leaders. These developments come as Definium steps up its engagement with both industry stakeholders and policymakers.